Breast Cancer: Epidemiology and Etiology

Cell Biochemistry and Biophysics

Volumn 72, Issue 2, 2015, Pages 333-338

  Tao, ZiQi ^a   Shi, Aimin ^b   Lu, Cuntao ^a   Song, Tao ^a   Zhang, Zhengguo ^a   Zhao, Jing ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Epidemiology; Etiology

Indexed keywords

BREAST NEOPLASMS; FEMALE; HUMAN;

BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84931268898     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0459-6     Document Type: Article

References (43)

1. Verma, R., Bowen, R. L., Slater, S. E., Mihaimeed, F., & Jones, J. L. (2012). Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. British Medical Bulletin,103, 129–145.
2. Druesne-Pecollo, N., Touvier, M., Barrandon, E., Chan, D. S., Norat, T., Zelek, L., et al. (2012). Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment,135, 647–654.
3. Youlden, D. R., Baade, P. D., Valery, P. C., Ward, L. J., Green, A. C., & Aitken, J. F. (2012). Childhood cancer mortality in australia. Cancer Epidemiology,36, 476–480.
4. Desantis, C., Ma, J., Bryan, L., & Jemal, A. (2014). Breast cancer statistics, 2013. CA A Cancer Journal for Clinicians,64, 52–62.
5. Hortobagyi, G. N., De La Garza Salazar, J., Pritchard, K., Amadori, D., Haidinger, R., Hudis, C. A., et al. (2005). The global breast cancer burden: Variations in epidemiology and survival. Clinical Breast Cancer,6, 391–401.
6. Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002). Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Research and Treatment,76, 27–36.
7. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature,406, 747–752.
8. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America,98, 10869–10874.
9. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007). Descriptive analysis of estrogen receptor (er)-negative, progesterone receptor (pr)-negative, and her2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the california cancer registry. Cancer,109, 1721–1728.
10. Iwase, H., Kurebayashi, J., Tsuda, H., Ohta, T., Kurosumi, M., Miyamoto, K., et al. (2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the japanese breast cancer society. Breast Cancer,17, 118–124.
11. Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clinical Cancer Research,16, 876–887.
12. Hudis, C. A. (2007). Trastuzumab—mechanism of action and use in clinical practice. New England Journal of Medicine,357, 39–51.
13. Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., van Limbergen, E., et al. (2005). Association between tumour characteristics and her-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. Journal of Clinical Pathology,58, 611–616.
14. Cadoo, K. A., Fornier, M. N., & Morris, P. G. (2013). Biological subtypes of breast cancer: Current concepts and implications for recurrence patterns. Quarterly Journal of Nuclear Medicine and Molecular Imaging,57, 312–321.
15. Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., et al. (2007). Differences in breast carcinoma characteristics in newly diagnosed african-american and caucasian patients: A single-institution compilation compared with the national cancer institute’s surveillance, epidemiology, and end results database. Cancer,110, 876–884.
16. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research,13, 4429–4434.
17. Morris, P. G., Murphy, C. G., Mallam, D., Accordino, M., Patil, S., Howard, J., et al. (2012). Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast Journal,18, 345–350.
18. Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Research and Treatment,115, 423–428.
19. Phipps, A. I., Chlebowski, R. T., Prentice, R., McTiernan, A., Wactawski-Wende, J., Kuller, L. H., et al. (2011). Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. Journal of the National Cancer Institute,103, 470–477.
20. Turpin, E., Bieche, I., Bertheau, P., Plassa, L. F., Lerebours, F., de Roquancourt, A., et al. (2002). Increased incidence of erbb2 overexpression and tp53 mutation in inflammatory breast cancer. Oncogene,21, 7593–7597.
21. Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiel, M. W., Kasumi, F., et al. (2002). Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Research,62, 560–566.
22. Barrow, T. M., & Michels, K. B. (2014). Epigenetic epidemiology of cancer. Biochemical and Biophysical Research Communications,455, 70–83.
23. Huang, G. L., Zhang, X. H., Guo, G. L., Huang, K. T., Yang, K. Y., Shen, X., et al. (2009). Clinical significance of mir-21 expression in breast cancer: Sybr-green i-based real-time rt-pcr study of invasive ductal carcinoma. Oncology Reports,21, 673–679.
24. Yan, L. X., Huang, X. F., Shao, Q., Huang, M. Y., Deng, L., Wu, Q. L., et al. (2008). Microrna mir-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA,14, 2348–2360.
25. Ambros, V. (2003). Microrna pathways in flies and worms: Growth, death, fat, stress, and timing. Cell,113, 673–676.
26. Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013). Deregulated serum concentrations of circulating cell-free micrornas mir-17, mir-34a, mir-155, and mir-373 in human breast cancer development and progression. Clinical Chemistry,59, 1489–1496.
27. Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010). Circulating micrornas as novel minimally invasive biomarkers for breast cancer. Annals of Surgery,251, 499–505.
28. Prabhu, J. S., Wahi, K., Korlimarla, A., Correa, M., Manjunath, S., Raman, N., et al. (2012). The epigenetic silencing of the estrogen receptor (er) by hypermethylation of the esr1 promoter is seen predominantly in triple-negative breast cancers in indian women. Tumour Biology,33, 315–323.
29. Wu, L., Wang, F., Xu, R., Zhang, S., Peng, X., Feng, Y., et al. (2013). Promoter methylation of brca1 in the prognosis of breast cancer: A meta-analysis. Breast Cancer Research and Treatment,142, 619–627.
30. Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D., Thompson, D., Ballinger, D. G., et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature,447, 1087–1093.
31. Hughes, S., Agbaje, O., Bowen, R. L., Holliday, D. L., Shaw, J. A., Duffy, S., & Jones, J. L. (2007). Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clinical Cancer Research,13, 6673–6680.
32. Gutierrez-Fernandez, A., Fueyo, A., Folgueras, A. R., Garabaya, C., Pennington, C. J., Pilgrim, S., et al. (2008). Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Research,68, 2755–2763.
33. Decock, J., Long, J. R., Laxton, R. C., Shu, X. O., Hodgkinson, C., Hendrickx, W., et al. (2007). Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Research,67, 10214–10221.
34. Gajdos, C., Tartter, P. I., Bleiweiss, I. J., Bodian, C., & Brower, S. T. (2000). Stage 0 to stage iii breast cancer in young women. Journal of the American College of Surgeons,190, 523–529.
35. Toriola, A. T., & Colditz, G. A. (2013). Trends in breast cancer incidence and mortality in the united states: Implications for prevention. Breast Cancer Research and Treatment,138, 665–673.
36. Desantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011). Breast cancer statistics, 2011. CA A Cancer Journal for Clinicians,61, 409–418.
37. Nelson, H. D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O’Meara, E. S., et al. (2012). Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Annals of Internal Medicine,156, 635–648.
38. Colditz, G. A. (2007). Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin. Breast Cancer Research,9, 108.
39. Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H. L., & Thun, M. (2006). Trends in breast cancer by race and ethnicity: Update 2006. CA A Cancer Journal for Clinicians,56, 168–183.
40. Olopade, O. I., Fackenthal, J. D., Dunston, G., Tainsky, M. A., Collins, F., & Whitfield-Broome, C. (2003). Breast cancer genetics in african americans. Cancer,97, 236–245.
41. Kogevinas, M., Porta, M. (1997). Socioeconomic differences in cancer survival: A review of the evidence. IARC Scientific Publications,138, 177–206.
42. McCormack, V. A., & Boffetta, P. (2011). Today’s lifestyles, tomorrow’s cancers: Trends in lifestyle risk factors for cancer in low- and middle-income countries. Annals of Oncology,22, 2349–2357.
43. Fan, L., Strasser-Weippl, K., Li, J. J., St Louis, J., Finkelstein, D. M., Yu, K. D., et al. (2014). Breast cancer in china. Lancet Oncology,15, e279–e289.